Im­mune De­sign buries its PhI­II work on can­cer, and in­vestors hit the pan­ic but­ton

More than a year af­ter tout­ing some ear­ly glim­mers of suc­cess for a com­bi­na­tion of their drug CMB305 and Tecen­triq (ate­zolizum­ab), Im­mune De­sign is throw­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER